scholarly journals Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials

Biometrics ◽  
2013 ◽  
Vol 69 (2) ◽  
pp. 301-309 ◽  
Author(s):  
Ying Huang ◽  
Peter B. Gilbert ◽  
Julian Wolfson
Keyword(s):  
Surrogate Markers ◽  
Vaccine Trials

scholarly journals Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 442
Author(s):  
Lorna Leal ◽  
Csaba Fehér ◽  
Valèria Richart ◽  
Berta Torres ◽  
Felipe García
Keyword(s):  
Antiretroviral Treatment ◽  
Therapeutic Vaccine ◽  
Treatment Interruption ◽  
Therapeutic Interventions ◽  
Surrogate Markers ◽  
Hiv Viral Load ◽  
Viral Control ◽  
Therapeutic Vaccines ◽  
Vaccine Trials ◽  
Therapy Interruption

A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials.

Despite Setbacks, Ca Vaccine Trials Continue

2011 ◽  
Vol 44 (5) ◽  
pp. 32
Author(s):  
NEIL OSTERWEIL
Keyword(s):  
Vaccine Trials

HPV VACCINE AND CERVICAL CANCER

2011 ◽  
pp. 108-115
Author(s):  
Vu Quoc Huy Nguyen
Keyword(s):  
Cervical Cancer ◽  
Relative Risk ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Preventive Strategy ◽  
Protective Effects ◽  
Papilloma Virus ◽  
Vaccine Trials ◽  
Close Relationship ◽  
The Relationship

Persistent infection with high-risk Human Papilloma Virus (HPV) has been identified as the causal factor of cervical cancer, with relative risk up to 300-400 folds. This very close relationship leads to the preventive strategy of vaccination against HPV infections and HPV-related lesions. The article describes molecular and immunologic characteristics of HPV, currently available HPV vaccines and its protective effects; the relationship between HPV vaccination and cervical cancer screening, and an introduction to therapeutic HPV vaccine trials.

Seeking participation in bovine TB vaccine trials

2021 ◽  
Vol 188 (10) ◽  
pp. 395-396
Author(s):  
Lindsay Heasman
Keyword(s):  
Vaccine Trials
Sign in / Sign up

Export Citation Format

Share Document